# Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)

> **NCT07243938** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tao Zhang** · enrollment: 70 (estimated)

## Conditions studied

- Locally Advanced Rectal Cancer (LARC)
- Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
- Metastatic Colorectal Cancer (mCRC)
- Neoadjuvant Therapy

## Interventions

- **RADIATION:** short-course radiotherapy
- **DRUG:** Zanidatamab
- **DRUG:** Tisleizumab(BGB-A317)
- **DRUG:** Capecitabine
- **DRUG:** Oxaliplatin
- **PROCEDURE:** TME surgery
- **DRUG:** S-1
- **PROCEDURE:** D2

## Key facts

- **NCT ID:** NCT07243938
- **Lead sponsor:** Tao Zhang
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-15
- **Primary completion:** 2028-07-30
- **Final completion:** 2031-06-01
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2025-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07243938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07243938, "Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)". Retrieved via AI Analytics 2026-08-20 from https://api.ai-analytics.org/clinical/NCT07243938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*